| Literature DB >> 17397958 |
Valerie Grum-Tokars1, Kiira Ratia, Adrian Begaye, Susan C Baker, Andrew D Mesecar.
Abstract
Although the initial outbreaks of the deadly coronavirus that causes severe acute respiratory syndrome (SARS-CoV) were controlled by public health measures, the development of vaccines and antiviral agents for SARS-CoV is essential for improving control and treatment of future outbreaks. One potential target for SARS-CoV antiviral drug development is the 3C-like protease (3CLpro). This enzyme is an attractive target since it is essential for viral replication, and since there are now a number of high resolution X-ray structures of SARS-CoV 3CLpro available making structure-based drug-design possible. As a result, SARS-CoV 3CLpro has become the focus of numerous drug discovery efforts worldwide, but as a consequence, a variety of different 3CLpro expression constructs and kinetic assays have been independently developed making evaluation and comparison between potential inhibitors problematic. Here, we review the literature focusing on different SARS-CoV 3CLpro expression constructs and assays used to measure enzymatic activity. Moreover, we provide experimental evidence showing that the activity of 3CLpro enzymatic is significantly reduced when non-native sequences or affinity-tags are added to the N- or C-termini of the enzyme, or when the enzyme used in assays is at concentrations below the equilibrium dissociation constant of the 3CLpro dimer. We demonstrate for the first time the utility of a highly sensitive and novel Alexa488-QSY7 FRET-based peptide substrate designed for routine analysis and high-throughput screening, and show that kinetic constants determined from FRET-based assays that are uncorrected for inner-filter effects can lead to artifacts. Finally, we evaluated the effects of common assay components including DTT, NaCl, EDTA and DMSO on enzymatic activity, and we recommend standardized assay conditions and constructs for routine SARS-CoV 3CLpro assays to facilitate direct comparisons between SARS-CoV 3CLpro inhibitors under development worldwide.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17397958 PMCID: PMC4036818 DOI: 10.1016/j.virusres.2007.02.015
Source DB: PubMed Journal: Virus Res ISSN: 0168-1702 Impact factor: 3.303
Fig. 1Schematic diagram of the translated SARS-CoV genomic RNA in which the open reading frames encoding the viral replicase polyproteins, pp1a and pp1ab, are depicted. The 3 sites recognized and processed by PLpro (red) and the 11 sites recognized and processed by 3CLpro (blue) are indicated. Complete processing of the 14 sites produces16 non-structural proteins (nsp's). Transmembrane regions are indicated as “TM”, and the polymerase (Pol) and helicase (Hel) coding regions are indicated.
FRET-peptide substrates utilized for SARS-CoV 3CLpro activity assays
aAttachment site of donor, fluorophore, or colorimetric label.
bAttachment site of quencher label.
Fig. 2SARS-CoV 3CLpro cleavage sites and the canonical recognition sequence. The 11 recognition sequences of SARS-CoV 3CLpro from the P6 to P5′ positions are shown with their respective locations between the respective nsp's. The relative kcat/Km values for the series of 11-mer peptide substrates are also given (Fan et al., 2005). A canonical recognition sequence is proposed based on the relative kcat/Km values for SARS-CoV 3CLpro, and the recognition sites of a series of other coronavirus 3C proteases (Kiemer et al., 2004, Thiel et al., 2003).
Dimer to monomer dissociation constants for various SARS-CoV 3CLpro constructs and mutants determined by different methods
| D ↔ M dissociation constant (μM) | Reference | ||||
|---|---|---|---|---|---|
| Nat | WT | 100% | 0.25–1.0 | Enzymatic | This work |
| N-H6-U | WT | <5% | >10.0 | Enzymatic | |
| N-H6-X | WT | 0.015 | Enzymatic and AGE | ||
| N-H6-X | WT | 0.00035 | AUC-SE | ||
| N-H6-X | 10aa-C145A | 0.0172 | |||
| C-H6-X | C145A-10aa | 0.0056 | |||
| C-H6-U | WT | 0.81 | enzymatic | ||
| C-H6-U | WT | 100 | AGE | ||
| C-H6-U | WT | 100% | 0.28 | AUC-SV | |
| Δ(1–3) | 76% | 3.4 | |||
| Δ(1–4) | 1.3% | 57.5 | |||
| C-H6-U | WT | 14.0 | AUC-SE | ||
| R4E | |||||
| C-H6-U | WT | 0.19 | AUC-SV | ||
| N-H6-U | WT | 100% | 227 | ITC | |
| Δ(1–7) | <1% | 262 | |||
| N-GSTX | 100% | <100 | |||
| Δ(1–5) | <1% | >100 | |||
Different constructs used in studies were: (Nat) native construct with n-terminal methionine; (N-H6U) n-terminal (His)6-tag uncleaved; (N-H6X) n-terminal (His)6-tag cleaved; (C-H6U) c-terminal (His)6-tag uncleaved; (C-H6X) c-terminal (His)6-tag cleaved; (N-GSTX) n-terminal GST-tag cleaved.
The wild type enzyme is defined as SARS 3CLpro purified from the particular construct. Delta (Δ) refers to the amino acid number(s) that were removed from the construct.
If a relative activity number is reported, it is based on the comparison to the wild type enzyme from the same construct.
The analytic method used to determine the dimer dissociation constant: (AUC) analytical ultracentrifugation; (SV) sedimentation velocity; (SE) sedimentation equilibrium; (ITC) isothermal titration calorimetry; (AGE) analytical gel exclusion chromatography; (DLS) dynamic light scattering.
WT(G278D) in these studies, the authors had a spurious mutation of G278D which they allowed to carry through all experiments so wild type is actually the G278D mutant (Shi and Song, 2006, Shi et al., 2004). The other indicated mutants are based on G278D.
DLS experiments were performed at 100 μM enzyme. The dissociation constants are based on either all dimer (Kd < 100 μM) or all monomer (>100 μM).
Fig. 3SDS-PAGE analysis of purified SARS-CoV 3CLpro constructs. The untagged version of the enzyme has a predicted molecular weight of 33.8 kDa. The (His)6-tagged construct, accordingly, is shifted to a slightly higher molecular. The native enzyme readily crystallizes in space group C2 (inset picture) when covalently modified by an inhibitor (Ghosh et al., 2005). In contrast, attempts to crystallize the (His)6-tagged construct in either its native or covalently modified form have been unsuccessful.
Fluorescence extinction coefficients (FECs) of various FRET-peptide substrates and their activity with SARS-CoV 3CLpro
| Alexa488-QSY7 | 37,840 ± 15 | 0.038 |
| Alexa594-QSY21 | 3,350 ± 100 | 0.003 |
| Dabcyl-Edans | 4,530 ± 150 | 0.068 |
| Abz-Tyr(NO2) | 830 ± 50 | 0.028 |
The specific sequence for each FRET-peptide substrate is described in Section 2.
The fluorescence extinction coefficient values (FECs) were determined from the slope of the line that was fit to the data in Fig. 4. The slope, or FEC value, resulted from a fit of the data to a line using linear regression.
The activity, i.e. turnover number was determined at a substrate concentration of 1 μM and a non-tagged enzyme concentration of 100 nM.
Fig. 4Fluorescence extinction coefficient (FEC) determination of four FRET-peptide substrates. The concentration of FRET-peptide was varied and plotted against the total arbitrary fluorescence values (AFUs) released upon complete cleavage of the substrate by an excess of SARS-CoV 3CLpro. Data were fit to a line to a line and the slope is the FEC constant in units of AFUs/μM. The FEC values and their errors are listed in Table 3.
Fig. 5Influence of an n-terminal (His)6-affinity tag and dimerization on the catalytic activity of SARS-CoV 3CLpro. Assays were performed in 100 μL reactions with 50 mM HEPES buffer, pH 7.5, using 1 μM of either the Alexa488-QSY7 or Dabcyl-EDANS FRET-peptide substrates. Data were fit to Eq. (1) and the resulting best-fit parameters for Alexa488-QSY7 were kcat = 0.097 ± 0.009 min−1 and Kd = 0.23 ± .12 μM, and for Dabcyl-EDANS were kcat = 0.32 ± 0.06 min−1 and Kd = 1.0 ± 0.5 μM.
Fig. 6X-ray structure of a substrate-like complex of SARS-CoV 3CLpro. A single monomer of a Cys145Ala mutant of the SARS-CoV 3CLpro dimer, having extended amino acid sequences at the n- and c-terminus, is shown as a surface representation (grey). The uncleaved, n-terminus of the second monomer of the dimer (yellow) extends into the active site. In addition, the c-terminus from a monomer in another asymmetric (cyan) also extends into the active site. The figure was made from PDB accession number 1Z1J (Hsu et al., 2005), using the program PyMOL version 0.99 (DeLano Scientific, LLC).